Nucleoside and nucleotide reverse transcriptase inhibitors in children (Q36885640)

16 August 2017

1 reference

title

Nucleoside and nucleotide reverse transcriptase inhibitors in children (English)

1 reference

16 August 2017

Anita De Rossi

5

0 references

Carlo Giaquinto

series ordinal

1

object named as

Carlo Giaquinto

1 reference

16 August 2017

3

Martina Penazzato

1 reference

16 August 2017

Osvalda Rampon

2

1 reference

16 August 2017

Federica Fregonese

series ordinal

4

1 reference

16 August 2017

Ruggiero D'Elia

series ordinal

6

1 reference

16 August 2017

publication date

1 January 2007

1 reference

Clinical Drug Investigation

16 August 2017

published in

1 reference

16 August 2017

volume

27

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

509-531

1 reference

Triple nucleoside reverse transcriptase inhibitor therapy in children

16 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00044011-200727080-00001

The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily

21 January 2018

1 reference

12 December 2020

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children

1 reference

12 December 2020

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

1 reference

12 December 2020

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

1 reference

12 December 2020

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

1 reference

12 December 2020

Retinal Toxicity in Human Immunodeficiency Virus–infected Children Treated With 2′,3′-Dideoxyinosine

1 reference

12 December 2020

Replication-dependent 65R-->K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V.

1 reference

12 December 2020

Current evidence for the use of paediatric antiretroviral therapy--a PENTA analysis. Paediatric European Network for the Treatment of AIDS Steering Committee.

1 reference

12 December 2020

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

1 reference

12 December 2020

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

1 reference

12 December 2020

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

1 reference

12 December 2020

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

1 reference

12 December 2020

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

1 reference

12 December 2020

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children

1 reference

12 December 2020

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

12 December 2020

Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

1 reference

12 December 2020

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

1 reference

12 December 2020

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

1 reference

12 December 2020

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy

1 reference

12 December 2020

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children

1 reference

12 December 2020

Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.

1 reference

12 December 2020

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1 reference

12 December 2020

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group

1 reference

12 December 2020

A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial

1 reference

12 December 2020

Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine

1 reference

12 December 2020

Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children

1 reference

12 December 2020

Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children

1 reference

12 December 2020

Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group

1 reference

12 December 2020

Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children

1 reference

12 December 2020

Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type

1 reference

12 December 2020

Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection

1 reference

12 December 2020

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours

1 reference

12 December 2020

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.

1 reference

12 December 2020

Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe

1 reference

12 December 2020

The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS.

1 reference

12 December 2020

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

1 reference

12 December 2020

A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection

1 reference

12 December 2020

Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults

1 reference

12 December 2020

Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria.

1 reference

12 December 2020

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children

1 reference

12 December 2020

Switching from protease inhibitor-based-HAART to a protease inhibitor-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children

1 reference

12 December 2020

Abacavir hypersensitivity reaction

1 reference

12 December 2020

PENTA guidelines for the use of antiretroviral therapy, 2004.

1 reference

12 December 2020

Risk factor analysis of hypersensitivity reactions to abacavir

1 reference

12 December 2020

Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine

1 reference

12 December 2020

Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus

1 reference

12 December 2020

Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children

1 reference

12 December 2020

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection

1 reference

12 December 2020

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection

1 reference

12 December 2020

Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter

1 reference

12 December 2020

Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children

1 reference

12 December 2020

NNRTI choice: has 2NN changed our practice?

1 reference

12 December 2020

A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team

1 reference

12 December 2020

Phase I Evaluation of Zalcitabine Administered to Human Immunodeficiency Virus-Infected Children

1 reference

12 December 2020

A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS

1 reference

12 December 2020

Human immunodeficiency virus type 1 phenotypes in children with advanced disease treated with long-term zalcitabine

1 reference

12 December 2020

Emtricitabine: a review of its use in the management of HIV infection

1 reference

12 December 2020

Abacavir hypersensitivity reaction in primary HIV infection

1 reference

12 December 2020

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

1 reference

12 December 2020

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

1 reference

12 December 2020

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects

1 reference

12 December 2020

Antiretroviral pharmacokinetics in the paediatric population: a review

1 reference

12 December 2020

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

1 reference

12 December 2020

Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee

1 reference

12 December 2020

A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions

1 reference

12 December 2020

Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.

1 reference

12 December 2020

Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1

1 reference

12 December 2020

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

1 reference

12 December 2020

Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate

1 reference

12 December 2020

Assessment of the relative potency of emtricitabine and lamivudine

1 reference

12 December 2020

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

12 December 2020

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir

1 reference

12 December 2020

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance

1 reference

12 December 2020

Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir

1 reference

12 December 2020

Pharmacokinetics of zidovudine in infants: a population analysis across studies

1 reference

12 December 2020

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team

1 reference

12 December 2020

Emtricitabine: an antiretroviral agent for HIV infection

1 reference

12 December 2020

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

12 December 2020

Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission

1 reference

12 December 2020

Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus

1 reference

12 December 2020

Pharmacokinetics of antiretroviral therapy in HIV-1-infected children

1 reference

12 December 2020

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells

1 reference

12 December 2020

A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trial.

1 reference

12 December 2020

Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection

1 reference

12 December 2020

Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection

1 reference

12 December 2020

1 reference

12 December 2020

A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team

1 reference

12 December 2020

Pharmacogenomics and HIV therapeutics

1 reference

12 December 2020

Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection

1 reference

12 December 2020

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

1 reference

12 December 2020

Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir

1 reference

12 December 2020

A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.

1 reference

12 December 2020

Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.

1 reference

12 December 2020

Immune Reconstitution after Receipt of Highly Active Antiretroviral Therapy in Children with Advanced or Progressive HIV Disease and Complete or Partial Viral Load Responsea

1 reference

12 December 2020

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).

1 reference

12 December 2020

Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine.

1 reference

12 December 2020

Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.

1 reference

12 December 2020

Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children

1 reference

12 December 2020

Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team

1 reference

12 December 2020

In vivo antagonism with zidovudine plus stavudine combination therapy

1 reference

12 December 2020

Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine

1 reference

12 December 2020

Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection

1 reference

12 December 2020

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

12 December 2020

First-line therapy and mitochondrial damage: different nucleosides, different findings

1 reference

12 December 2020

10.2165/00044011-200727080-00001

Identifiers

DOI

1 reference

16 August 2017

1 reference